09989.HK
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 4.23
−0.59%Year over year
Reported trailing growth
- Revenue
- -0.4%
- EBITDA
- -35.3%
- EBIT
- -56.7%
- EPS
- -49.9%
- Free cash flow
- -19.0%
- Operating cash flow
- +42.9%
Forward estimates
Based on analyst estimates
- Revenue
- -21.6%
- EBITDA
- +105.1%
- EPS
- +120.2%
Three-year CAGR
- Revenue
- -8.5%
- EBITDA
- -14.9%
- EBIT
- -17.6%
- Net income
- -21.7%
- EPS
- -21.7%
- Free cash flow
- -20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026